SMARCA4 and cancer: Thus vulnerability to AURKA inhibitors might not be limited to the loss of SMARCA4 in NSCLCs but might occur in other cancers with mutations in SMARCA4 or other SWI/SNF components that cause a loss of SWI/SNF function.